Speaker Profile
GWENDOLYN M. WISE BLACKMAN
Gwen Wise-Blackman, Ph.D. has 20 years of combined experience in Cell-Based Assays and Quality Systems. She has worked at DuPont Pharmaceuticals, Catalent Pharma Solutions (formerly Magellan Laboratories and Cardinal Health), and Salix Pharmaceuticals where she successfully managed multiple projects and held positions of increasing accountability for scientific and quality expertise. Currently, she is the owner of Gwen Wise-Blackman Consulting, LLC, a biopharmaceutical consulting firm. Her focus has been in High-Throughput Screening, Cell-Based Assay Method Development and Validation, Ligand Binding Methods, Technology Transfer, GxP Regulations, and Quality Assurance. Dr. Wise-Blackman has a Bachelor of Science degree in biology from M.I.T and a Ph.D. in Pharmacology from the University of Virginia. She is a member of ASQ and AAPS.

Gwendolyn M. Wise Blackman
October 21 2025
01 : 00 PM EST
90 Minutes
Bioanalysis of Oligonucleotide Therapeutics: Problems, Pitfalls, and Strategies for Success
Cell and gene therapy is an exploding area of new technology and innovation in the pharmaceutical industry. Mapping of the human genome that led to discovery of pathways for intervention in disease states drives this innovation in drug development. Many of these discoveries are improving the prognosis of diseases that previously had no therapeutic intervention. As small molecules coupled to larg..